FGI-104

FGI-104 is the name of an experimental broad-spectrum antiviral drug, with activity against a range of viruses including Hepatitis B, Hepatitis C, HIV, Ebola virus, and Venezuelan equine encephalitis virus. 
Mechanism.
The drug acts by inhibiting the protein TSG101, which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice from Ebola virus disease.